2023
DOI: 10.1152/physiol.2023.38.s1.5726031
|View full text |Cite
|
Sign up to set email alerts
|

Chronic cannabigerol administration lowers blood pressure in phenotypically normal mice

Abstract: Cannabigerol (CBG), the precursor of the major cannabinoid compounds synthesized from Cannabis sativa L., has emerged as a novel potential therapeutic target due to its lack of psychoactive effects and efficacy at reducing pain and inflammation in animal models. Despite this, little is known about the safety of CBG, including its impact on cardiovascular function. Our laboratory recently showed that acute CBG administration lowers blood pressure, by over 20 mmHg, in phenotypically normal male mice via an α2-ad… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 0 publications
0
0
0
Order By: Relevance